32896-02-9

Usage

Uses

Used in Organic Synthesis:
3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE is used as a building block for the synthesis of more complex chemical structures, such as pharmaceuticals and materials, due to its unique molecular structure and reactivity.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE is used as a key intermediate in the development of new drugs and therapeutic agents, leveraging its chemical properties to create novel and effective pharmaceutical compounds.
Used in Material Science:
3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE is utilized in material science for the synthesis of advanced materials with specific properties, such as conductivity, stability, or reactivity, by incorporating its unique molecular structure into the material's composition.

Upstream product

• 3141-26-2 3,4-dibromothiophene 
• 5374-05-0 (dichloromethoxy)ethane 
• 3141-25-1 2,3,4-tribromothiophene 
• 68-12-2 N,N-dimethyl-formamide 
• 2591-86-8 N-Formylpiperidine 
• 3958-03-0 Tetrabromothiophene 

Downstream Products

• 189745-63-9 4-(3,4-dibromothien-2-yl)methanol-1-trityl-imidazole 
• 189745-66-2 (3,4-dibromo-thiophen-2-yl)-(1-trityl-1H-imidazol-4-yl)-methanone 
• 1360605-09-9 3-(3,5-dimethylisoxazol-4-yl)-4-(4-hydroxyphenyl)thiophene-2-carbaldehyde 
• 1360604-75-6 3-(3,5-dimethylisoxazol-4-yl)-4-(4-hydroxyphenyl)thiophene-2-carbaldehyde oxime 
• 125493-06-3 6-bromothieno[3,2-b]thiophene-2-carboxylic acid 
• 1312099-10-7 N-(4-(4-bromo-2-formylthiophen-3-yl)-3-methylphenyl)methanesulfonamide 
• 1312098-23-9 3-(4-(4-chloro-2-methoxyphenyl)-3-(4-hydroxyphenyl)thiophen-2-yl)propanoic acid 
• 1312098-74-0 ethyl 3-(4-(4-chloro-2-methoxyphenyl)-3-(4-hydroxyphenyl)thiophen-2-yl)propanoate 
• 1312098-72-8 (E)-ethyl 3-(4-(4-chloro-2-methoxyphenyl)-3-(4-hydroxyphenyl)thiophen-2-yl)acrylate 
• 1353572-40-3 4-bromo-3-(4-hydroxyphenyl)thiophene-2-carbaldehyde 
• 1312098-71-7 4-bromo-3-(4-hydroxyphenyl)thiophene-2-carbaldehyde 
• 25121-83-9 3-bromothieno<3,2-b>thiophene 
• 1098608-28-6 ethyl 6-bromothieno[3,2-b]thiophene-2-carboxylate 

Relevant academic research and scientific papers

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

Synthesis, characterization and organic field-effect transistors applications of novel tetrathienoacene derivatives

Two novel organic semiconductors with tetrathienoacene (TTA) as the central core end-capped with 5-hexyl-2-thiophene, (Hex-T)2-TTA, and 4-hexyl-phenyl, (Hex-Ph)2-TTA, have been synthesized and investigated for organic field effect transistor (OFET) applications. The novel TTA derivatives were characterized by thermal gravimetric analysis, differential scanning calorimetry, UV–Vis spectroscopy, and cyclic voltammetry as well as studied by density functional theory calculations. Two types of OFETs with the solution and vacuum-deposited active layer were fabricated and characterized. Both TTA-derivatives demonstrated electroluminescence in OFETs, and (Hex-Ph)2-TTA showed ambipolar charge transport with the hole mobility as high as 0.68 cm2 V?1s?1.

Isomeric effect of fluorene-based fused-ring electron acceptors to achieve high-efficiency organic solar cells

Acceptor-donor-acceptor (A-D-A) non-fullerene electron acceptors (NFEAs) using ladder-type donor structures have become the dominant n-type materials for achieving high-efficiency OSCs. In this work, two isomeric fluorene-based ladder-type structures FCTT (TT-C-F-C-TT) and FTCT (T-C-TFT-C-T) have been designed and synthesized. These two isomeric donors with the different fused-ring arrangement, molecular geometry, and side-chain placement were end-capped with the FIC acceptors to form two NFEAs FCTT-FIC and FTCT-FIC isomeric materials. Compared to FTCT-FIC using the thiophene (T)-terminal donor, FCTT-FIC with the thienothiophene (TT)-terminal donor has more evenly distributed side chains on both sides of the backbone and less steric hindrance near the FIC acceptors, which enables stronger antiparallel π-π packing among the end-groups to create a channel for efficient electron transport, as evidenced by the thin-film GIWAXS measurements. FCTT-FIC displayed a larger optical bandgap and deeper-lying energy levels than its FTCT-FIC isomer. Compared to the PBDB-T:FTCT-FIC device, the PBDB-T:FCTT-FIC device showed a higher PCE of 10.32% with an enhanced Jsc of 19.63 mA cm-2 and an FF of 69.14%. A PM6:FCTT-FIC device using PM6 as a p-type polymer achieved the highest PCE of 12.23%. By introducing PC71BM as the second acceptor to enhance the absorption at shorter wavelengths, optimize the morphology and facilitate electron transport, the ternary-blend PM6:FCTT-FIC:PC71BM (1 : 1 : 0.5 in wt%) device yielded the highest PCE of 13.37% with a Voc of 0.92 V, a higher Jsc of 19.86 mA cm-2, and an FF of 73.2%. This result demonstrated that the TT-terminal ladder-type donor is generally a better molecular design than the corresponding T-terminal ladder-type isomer for the development of new A-D-A NFEAs.

Synthetically controlling the optoelectronic properties of dithieno[2,3-d:2′,3′-d′]benzo[1,2-b:4,5-b′] dithiophene-alt-diketopyrrolopyrrole-conjugated polymers for efficient solar cells

We have demonstrated that, by changing the substituent groups on dithieno[2,3-d:2′,3′-d′]benzo[1,2-b:4,5-b′]dithiophene (DTBDT), one could effectively and rationally tune the energy levels, optical band gaps and charge transporting properties, etc. of the DTDBT derivatives (DTBDTs) and their conjugated polymers (CPs) and diketopyrrolopyrrole (DPP) derivatives. the Partner Organisations 2014.

Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists

The optimization of a series of thieno[3,2-b]thiophene-2-carboxylic acid derivatives for agonist activity against the GPR35 is reported. Compounds were optimized to achieve β-arrestin-biased agonism for developing probe molecules that may be useful for elucidating the biology and physiology of GPR35. Compound 13 was identified to the most potent GPR35 agonist, and compounds 30 and 36 exhibited the highest efficacy to cause β-arrestin translocation.

SUBSTITUTED THIOPENES OR FURANS AS ESTROGEN RECEPTOR LIGANDS

The invention provides: a compound of Formula (I) or a pharmaceutically acceptable ester, amide, or salt thereof, including a salt of such an ester or amide, wherein A, B, R1, R2, R4, R5, R6 and Rsup

NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE

The present invention is directed to novel thiophene inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Pharmaceutical compounds

This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.

4-(THIEN-2-YL)METHYL]-IMIDAZOLE ANALGESICS

The 4-[(thien-2-yl)methyl]-imidazoles of the formulae: STR1 wherein R is hydrogen or methyl,X is hydrogen, C 1-4 alkyl, bromine or chlorine, andY is hydrogen, C 1-4 alkyl, bromine or chlorine;with the proviso that X and Y are not both simultaneously hydrogen.have exceptional analgesic activity.